Streamlining Pharma Drug Development: Yes, It’s Time. - White Paper
Supply Chain Management
Friday, May 27, 2016
The path from molecule to market isn’t getting any easier. A new model for success: focus on what you do best — and outsource the rest.
The costs of drug development continue to rise. Dramatically. According to a 2015 report by Deloitte, costs have increased by a third in just the last five years. If that weren’t trouble enough, sales during the same time frame have tumbled 50%. Increased expenditure and decreased income are a bad combination — especially in an industry where the average cost to bring a new product to market approaches $2.6 billion. It also helps explain why the ROI on R&D is also down 50%.
Please complete the short form below to download this whitepaper.